Developments in tissue engineered and regenerative medicine products summarizes recent developments in tissue engineering and regenerative medicine with an emphasis on commercialization and product development. Features of current cell therapy and tissue engineered products which have facilitated successful commercialization are emphasized and roadblocks to successful product development are also highlighted. Preclinical and clinical testing of tissue engineered and regenerative medicine products, regulatory, quality control, manufacturing issues, as well as generating and securing intellectual property and freedom to operate considerations are presented. This book represents a complete 'how-to' manual for the development of tissue engineered and regenerative medicine products from conceptualization to clinical trial to manufacturing.

Key Features

  • Addresses practical considerations for the field of tissue engineering and regenerative medicine from the perspective of the biotechnology industry
  • Written as a manual for tissue engineering and regenerative medicine product development applicable to the US and EU
  • Illustrates pathway integration of science and business required for successful product development


Industry professionals and entrepreneurial academics contemplating new start-ups focused on tissue engineering and regenerative medicine; Entrepreneurially minded students interested in biotechnology

Table of Contents

Overview of tissue engineering/regenerative medicine; Cells; Biomaterials for TE/RM products; Neo-Bladder: A foundational technology platform for tubular organ regeneration; Neo-Urinary Conduit™; Tissue engineering of non-bladder tubular organs; Tissue engineering of solid organs; Regulatory and quality control; Pre-clinical and clinical evaluation of TE/RM products; Manufacturing; Intellectual property.


No. of pages:
© 2012
Woodhead Publishing
Print ISBN:
Electronic ISBN:

About the editors

Joydeep Basu

Dr Joydeep Basu is Senior Scientist, Bioprocess R&D, Tengion Inc., in Winston-Salem, North Carolina, USA. He has over 10 years' experience in the creation, research and development of cell therapy, gene therapy, regenerative medicine and tissue engineered products within entrepreneurial biotechnology companies including Athersys Inc (Cleveland, USA) and Tengion Inc (North Carolina, USA). Dr. Basu is a recognized global authority on the development of non-integrative gene therapy products and has published and presented broadly within the field of regenerative medicine/tissue engineering. He is currently focused on driving development of Tengion's tubular organ regeneration platform technology for applications beyond regeneration of bladder.

John Ludlow

Dr John W. Ludlow is Senior Director, Process Research and Assay Development, Tengion Inc., in Winston-Salem, North Carolina, USA. With experiences as Director of the Cell Therapy Program at Incara Pharmaceuticals, and Senior Director of the Cell Therapy Program at Vesta Therapeutics (North Carolina, USA), he has achieved demonstrable successes in managing and directing therapeutic area-specific research and regenerative medicine and tissue engineering product development. Responsibilities have included bringing new products into bioprocessing research and development, taking new products to demonstration in animal models, GLP and non-GLP production, and initiation of human clinical trial sites. Dr. Ludlow has previous held faculty memberships at the Rochester Institute of Technology and the University of Rochester Cancer Center, with authorship on over 80 scientific publications.

Affiliations and Expertise

Tengion Inc, USA